Introduction
Study Identifier | Phase | Experiment Drug | Involved target | Disease condition | Primary Outcome Measures | Study Status | Study Results |
---|---|---|---|---|---|---|---|
Clinical trials targeting transmembrane transport | |||||||
NCT04918186 | II | BA3011(BA3021) + Durvalumab | Axl (ROR2) | platinum resistant high grade serous ovarian cancer | ORR | Recruiting | NA |
NCT01335958 | I | DMUC5754A | MUC16 | Platinum-Resistant Ovarian Cancer | DLTs | Completed, published | Grade ≥3-related AE in ≥5%, anti-tumor activity in MUC16-high patients |
NCT02146313 | I | DMUC4064A | MUC16 | Platinum-Resistant Ovarian Cancer | DLTs, MTD, PR2D, AEs, sAEs | Completed published | grade ≥ 3 toxicities in 25% RP2D: 5.2 mg/kg, CBR: 46% in MUC16-high patients |
NCT01469793 | I | DMOT4039A | Mesothelin | Platinum-Resistant Ovarian Cancer | MTD, DLTs RP2D | Completed, published | RP2D: 2.4 mg/kg (q3w) and 1.0 mg/kg (q1w); SAE:8.5% |
NCT02751918 | Ib | BAY94-9343+PLD | Mesothelin | Mesothelin-expressing Platinum-resistant Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer | MTD, AEs | Completed published | ORR: 27.7% (all) ORR: 42.1% (high mesothelin expression) MTD: 6.5 mg/kg The most common AE: nausea (47.7%) |
NCT01363947 | I | DNIB0600A | NaPi2b | Non-mucinous and platinum-resistant ovarian cancer | AEs, DLTs, RP2D, OR, DOR | Completed published | grade ≥3 neutropenia (10%) RP2D: 2.4 mg/kg(q3w) All RECIST responses (NaPi2b-high) |
NCT04504916 | II | Zilovertamab Vedotin | ROR1 | platinum-resistant ovarian cancer | ORR, TTR, DOR, PFS, OS | Completed | NA |
NCT02539719 | 1a/1b | Tamrintamab pamozirine | DPEP3 | platinum-resistant/refractory ovarian cancer | AEs, ORR | Completed published | ORR:4% (intolerable) Higher response in higher DPEP3 |
Clinical trials targeting DDR | |||||||
NCT02595892 | II | Gemcitabine Hydrochloride + M6620 | ATR | recurrent, platinum-resistant high-grade serous ovarian cancer | PFS, ORR | Completed published | Show some benefits of adding M6620 to gemcitabine (PFS: 22.9w vs 14.7w) |
NCT04149145 | I | M4344+Niraparib | ATR | PARPi-resistant advanced epithelial serous ovarian cancer, primary peritoneal cancer, or fallopian tube cancer | AEs, MTD | Not yet recruiting | NA |
NCT03462342 | I | AZD6738+ Olaparib | ATR | Recurrent platinum-sensitive and platinum-resistant HGSOC | AEs, ORR, PFS | Recruiting | NA |
NCT03704467 | Ib//II | Carboplatin + M6620 + Avelumab | ATR | PARPi-resistant Ovarian Cancer | DLT, AEs | Recruitment completed | NA |
NCT01164995 | II | MK-1775 + carboplatin | WEE1 | Refractory or Platinum Resistant Ovarian Cancer with TP53 mutation | AEs, antitumor activity (CT/CA125) | Completed published | ORR: 41%, PFS: 5.6m AE: bone marrow toxicity, nausea and vomiting |
NCT03579316 | II | AZD1775+ olaparib | WEE1 | PARPi-resistant ovarian cancer | ORR, safety and tolerability | Recruiting | NA |
NCT02272790 | II | Adavosertib+ Carboplatin/ PLD/Paclitaxel/ Gemcitabine | WEE1 | Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | ORR, AEs | Completed published | ORR (overall):31.9% ORR (adavosertib+ Carboplatin):66.7% Grade ≥3 AEs: anemia (33%), neutropenia (45.7%), Thrombocytopenia (31.9%) |
NCT05198804 | I/II | ZN-c3 + Niraparib | WEE1 | Platinum-/PARPi-Resistant Ovarian Cancer | DLTs, PFS, ORR | Recruiting | NA |
NCT04516447 | I | ZN-c3+ PLD/carboplatin/ paclitaxel/gemcitabine | WEE1 | Platinum-Resistant Ovarian, Peritoneal or Fallopian Tube Cancer | AEs, MTD, RP2D | Recruiting | NA |
NCT02101775 | II | Gemcitabine with or without MK-1775 | WEE1 | Recurrent, Platinum Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers | PFS, OR, OS, AEs | Completed published | PFS: 4.6 months vs 3.0 months (HR 0.56, 95%CI:0.35 to 0.90, p=0.015). OS: 11.5 months vs 7.2 months (HR 0.56, 95%CI 0.34 to 0.92, p=0.022). PR rate: 21% vs 3% (p=0.02) |
NCT02203513 | II | LY2606368 | CHK1/2 | recurrent platinum-resistant HGSOC with BRCA wild-type or mutation | ORR | Partially completed (BRCA wide-type), recruitment ongoing | PR (assessable per protocol): 33% (8/24), Grade≥3AEs: neutropenia (93%); reduced white blood cell count (82%); thrombocytopenia (25%), anemia (11%). |
NCT03414047 | II | LY2606368 | CHK1/2 | platinum-resistant HGSOC with BRCA wild-type or mutation | ORR | Completed | In platinum resistant patients: ORR (Cohorts 1--3): 12.1% DCR was 37.1%, |
NCT04678102 | I | PHI-101 | CHK2 | Platinum Resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancers | DLT, MTD | Recruiting | NA |
NCT02797964 | I/II | SRA737 | CHK1 | Platinum-resistant or intolerant HGSOC | AEs, MTD | Completed | MTD: 1000 mg QD RP2D: 800 mg QD Mild toxicities |
Clinical trials targeting signaling pathway | |||||||
NCT03875820 | I | Defatcinib+VS-6766 | MAPK | LGSOC without conventional treatment | Estabilsh tolerated dose and Measure. AEs | Active, not recruiting | NA |
NCT03648489 | II | TAK228 | PI3K/AKT/mTOR | platinum-resistant ovarian cancer | PFS | Active, not recruiting | NA |
NCT03586661 | I | Copanlisib | PI3K/AKT | platinum-resistant ovarian cancer with BRCA mutation | MTD and RP2D | Active, not recruiting | NA |
NCT04374630 | II | Afuresertib+paclitaxel | PI3K/AKT | Platinum-Resistant Ovarian Cancer | PFS | Recruiting | NA |
NCT04586335 | I | CYH33 | PI3K/AKT | Platinum-/PARPi-Resistant Ovarian Cancer | DLT, ORR | Recruiting | NA |
NCT04055649 | II | ONC201 | PI3K/AKT、MAPK | Platinum Refractory or Resistant Ovarian Cancer | AEs, DLT's, ORR, PFS | Recruiting | NA |
NCT05295589 | II | Copanlisib | PI3K/AKT | Recurrent Platinum Resistant Ovarian Cancer | PFS | Not yet recruiting | NA |
NCT03363867 | II | Cobimetinib | MAPK | Recurrent Platinum Resistant High Grade Serous Ovarian Cancer | ORR | Recruiting | NA |
NCT03639246 | I/II | AVB-S6-500 | GAS6-AXL | platinum-resistant Recurrent Ovarian Cancer | AEs PFS | Completed published | ORR (AVB-500 + PAC): 34.8% median DoR, PFS, and OS (AVB-500 + PAC):7.0, 3.1, and 10.3 months, respectively RP2D (AVB-500): 15 mg/kg |
NCT04019288 | I/II | AVB-S6-500 | GAS6-AXL | Platinum-Resistant Ovarian cancer | AEs | Completed published | no DLTs and grade ≥3 AEs within 6-week Exploratory studies are ongoing. |
NCT04893551 | I | Tilvestamab | GAS6-AXL | Platinum-resistant relapsed HGSOC | AEs | Terminated | NA |
NCT01952249 | Ib | Demcizumab+paclitaxel | Notch | platinum-resistant ovarian, primary peritoneal, and fallopian tube cancer | DLTs | Completed | RP2D: 3.5mg/kg tolerability, clinical activity, |
NCT03776812 | II | Relacorilant + Nab-Paclitaxel | GR | recurrent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer | PFS, ORR, DOR | Completed | ORR is similar among arms (35%); Intermittent arm: OS, 13.9 months, PFS, 5.6 months Continuous arm; OS months, 11.3, PFS, 5.3 months Nab-paclitaxel: OS, 12.2 months, PFS, 3.8 months |
NCT03319628 | 1/II | XMT-1536 | NaPi2b | platinum-resistant ovarian cancer | MTD and RP2D | Recruiting | NA |
NCT04502602 | 1/1b | Niraparib + Neratinib | HER2 | Platinum-resistant Ovarian Cancer | RP2D, PFS, AEs | Recruiting | NA |
NCT03287271 | I/II | Defactinib (VS-6063) +Carboplatin/PaclitaxeL | FAK | Carboplatin-resistant Ovarian Cancer | ORR, AEs | Recruiting | NA |
Clinical trials targeting epigenic modification | |||||||
NCT05327010 | II | ZEN003694 +Talazoparib | BET bromodomain | PARPi-resistant recurrent ovarian cancer with BRCA mutation or DDR aberrations | ORR | Recruiting | NA |
NCT04840589 | I | ZEN003694+nivolumab+/- Ipilimumab | BET bromodomain | Recurrent Platinum-Resistant Ovarian Carcinoma | RP2D | Recruiting | NA |
NCT03206047 | I/II | atezolizumab+/-Guadecitabine+/-CDX-1401 vaccine | DNMT | platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma | AEs, PFS | Recruiting | NA |
NCT02901899 | II | Guadecitabine + Pembrolizumab | DNMT | recurrent platinum resistant ovarian cancer | ORR | Complete | PR: 8.6%; SD:22.9%; CBR: 31.4% (95% CI: 16.9%-49.3%); duration of clinical benefit was 6.8 months |